Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023:1442:45-64.
doi: 10.1007/978-981-99-7471-9_4.

Metabolism in Hematopoiesis and Its Malignancy

Xiaoyuan Zeng  1 , Yi-Ping Wang  2 , Cheuk-Him Man  3
Affiliations

Metabolism in Hematopoiesis and Its Malignancy

Xiaoyuan Zeng et al. Adv Exp Med Biol. 2023.

Abstract

Hematopoietic stem cells (HSCs) are multipotent stem cells that can self-renew and generate all blood cells of different lineages. The system is under tight control in order to maintain a precise equilibrium of the HSC pool and the effective production of mature blood cells to support various biological activities. Cell metabolism can regulate different molecular activities, such as epigenetic modification and cell cycle regulation, and subsequently affects the function and maintenance of HSC. Upon malignant transformation, oncogenic drivers in malignant hematopoietic cells can remodel the metabolic pathways for supporting the oncogenic growth. The dysregulation of metabolism results in oncogene addiction, implying the development of malignancy-specific metabolism-targeted therapy. In this chapter, we will discuss the significance of different metabolic pathways in hematopoiesis, specifically, the distinctive metabolic dependency in hematopoietic malignancies and potential metabolic therapy.

Keywords: Hematopoiesis; Hematopoietic malignancy; Metabolism; Metabolism-targeted therapy; Nutrient metabolism.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Advani AS et al (2018) Report of the relapsed/refractory cohort of SWOG S0919: a phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML). Leuk Res 67:17–20. https://doi.org/10.1016/j.leukres.2018.01.021 - DOI - PubMed - PMC
    1. Appelbaum FR (2007) Hematopoietic-cell transplantation at 50. N Engl J Med 357:1472–1475. https://doi.org/10.1056/NEJMp078166 - DOI - PubMed
    1. Balakrishnan K, Ravandi F, Bantia S, Franklin A, Gandhi V (2013) Preclinical and clinical evaluation of forodesine in pediatric and adult B-cell acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk 13:458–466. https://doi.org/10.1016/j.clml.2013.04.009 - DOI - PubMed - PMC
    1. Baryawno N et al (2019) A cellular taxonomy of the bone marrow stroma in homeostasis and leukemia. Cell 177:1915–1932.e1916. https://doi.org/10.1016/j.cell.2019.04.040 - DOI - PubMed - PMC
    1. Behan JW et al (2009) Adipocytes impair leukemia treatment in mice. Cancer Res 69:7867–7874. https://doi.org/10.1158/0008-5472.Can-09-0800 - DOI - PubMed - PMC

LinkOut - more resources